- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.24 | Spago's CEO: "We want to expand cancer treatment with effective radiopharmaceuticals" | 3 | Cision News | ||
| 18.12.24 | Second Patient Group Successfully Dosed in Spago Nanomedical's Phase I/IIa Study Tumorad-01 | 242 | ACCESSWIRE | LUND, SE / ACCESSWIRE / December 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that all patients in the second patient group have been dosed according... ► Artikel lesen | |
| 06.11.24 | Spago Nanomedical Interim Report January-September 2024 | 188 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / November 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Progress for the Tumorad programJULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 485 (KSEK... ► Artikel lesen | |
| 21.10.24 | Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2025 | 194 | ACCESSWIRE | LUND, SE / ACCESSWIRE / October 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM")... ► Artikel lesen | |
| SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 01.10.24 | Spago Nanomedical in New Phase with Full Focus on the Tumorad Program | 251 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / October 1, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Board of Directors of Spago Nanomedical AB (publ) has decided that the company's resources will be focused... ► Artikel lesen | |
| 18.09.24 | Four-hands Dinner at Spago Budapest | 1 | BBJ online | ||
| 05.09.24 | Spago Nanomedical strengthened management to reflect project progress | 2 | Cision News | ||
| 27.08.24 | Spago Nanomedical's Phase I/IIa Study Tumorad-01 Continues Following Successful Treatment Completion of First Patient Group | 300 | ACCESSWIRE | LUND, SE / ACCESSWIRE / August 27, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that the independent Data Monitoring Committee (DMC) recommends to proceed... ► Artikel lesen | |
| 21.08.24 | Spago Nanomedical Interim Report January-June 2024 | 304 | ACCESSWIRE | LUND, SE / ACCESSWIRE / August 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Clinical and non-clinical progress in the Tumorad program APRIL - JUNE IN BRIEFNet sales for the quarter amounted... ► Artikel lesen | |
| 10.06.24 | Bulletin from the 2024 Annual General Meeting of Spago Nanomedical AB | 229 | ACCESSWIRE | LUND, SE / ACCESSWIRE / June 10, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, June 10, 2024, at which the AGM resolved... ► Artikel lesen | |
| 23.05.24 | Spago Nanomedical Receives Declarations of Intent from the Largest Owner, Board and Management Team Regarding the Exercise of TO12 | 269 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / May 23, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") has received declarations of intent from, among... ► Artikel lesen | |
| 20.05.24 | Spago Nanomedical Provides an Update on Tumorad-01 - Trial Proceeds as Planned | 542 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / May 20, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that both of the clinical sites in the phase I/IIa study Tumorad-01... ► Artikel lesen | |
| 17.05.24 | The Exercise Period for Spago Nanomedical's Warrants of Series TO12 Commences Today | 389 | ACCESSWIRE | LUND, SE / ACCESSWIRE / May 17, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") issued a total of 127,321,212 warrants of series... ► Artikel lesen | |
| 16.05.24 | Spago Nanomedical Publishes the Annual Report for 2023 | 259 | ACCESSWIRE | LUND, SE / ACCESSWIRE / May 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2023 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen | |
| 06.05.24 | Notice To Annual General Meeting of Spago Nanomedical AB | 290 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / May 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the annual general meeting is for convenience only. The Swedish version prevails... ► Artikel lesen | |
| 02.05.24 | Spago Nanomedical Interim Report January-March 2024 | 367 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / May 2, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Positive start to an important yearJANUARY - MARCH IN BRIEFNet sales for the quarter amounted to KSEK 350 (KSEK... ► Artikel lesen | |
| 24.04.24 | Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad | 597 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today data from a non-clinical study exploring 177Lu-SN201 in a model for... ► Artikel lesen | |
| 16.04.24 | Spago Nanomedical Strengthens Management with Head of CMC & Supply | 311 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / April 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced the appointment of Birgitta Rembratt Svensson as Head of CMC & Supply.... ► Artikel lesen | |
| 07.02.24 | Spago Nanomedical Year-end Report January-December, 2023 | 367 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / February 7, 2024 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) First cancer patient dosed with Tumorad®OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK... ► Artikel lesen | |
| 18.01.24 | Spago Nanomedical Presents at Redeye's Fight Cancer Event on January 24 | 312 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / January 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company will participate at Redeye's Fight Cancer event... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 43,000 | +6,09 % | SpringWorks Therapeutics jumps amid takeover speculation | ||
| ADMA BIOLOGICS | 18,560 | 0,00 % | ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock? | ||
| QIAGEN | 44,095 | -0,20 % | Qiagen schließt Partnerschaft mit Genomics England ab | DJ Qiagen schließt Partnerschaft mit Genomics England ab
DOW JONES--Qiagen schließt eine Partnerschaft mit Genomics England ab. Ziel ist es, die Durchführung der Generation Study zu unterstützen.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,390 | -1,64 % | 2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy | ||
| RECURSION PHARMACEUTICALS | 6,880 | -5,30 % | Recursion Pharmaceuticals: Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More | REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsREC-4539... ► Artikel lesen | |
| NUVALENT | 76,61 | -2,18 % | Nuvalent-Forschungschef verkauft Aktien im Wert von 197.853 US-Dollar | ||
| AVIDITY BIOSCIENCES | 29,460 | -1,44 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,020 | -12,25 % | Vera Therapeutics (NASDAQ:VERA) Stock Price Down 7.3% - Should You Sell? | ||
| TEMPUS AI | 37,520 | +0,13 % | Tempus AI (NASDAQ:TEM) Trading Down 3.6% Following Insider Selling | ||
| KYMERA THERAPEUTICS | 38,170 | -5,80 % | Analysts Issue Forecasts for KYMR FY2029 Earnings | ||
| HARMONY BIOSCIENCES | 33,860 | -1,93 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,840 | -31,25 % | Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1 | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).... ► Artikel lesen | |
| IMMUNOVANT | 23,480 | -0,70 % | Immunovant-Finanzchefin Eva Renee Barnett verkauft Aktien im Wert von 98.930 US-Dollar | ||
| BIONTECH | 119,40 | -0,50 % | BioTech-Rally 2025: Evotec, BioNTech, Vidac Pharma, Pfizer und Bayer sind auf der Kaufliste | Zwei Jahre tat sich nun fast gar nichts im BioTech-Sektor. Nicht einmal der in 2024 eingeläutete Zinssenkungstrend konnte die Investoren zu größeren Investments bewegen. Dafür haben die KI- und Hightech-Aktien... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 3,655 | -14,80 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate... ► Artikel lesen |
SPAGO NANOMEDICAL AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +4,00 % bei einem Aktienkurs von 0,016 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.
